Video: Sitting Down With… John Tomtishen
Catalent’s John Tomtishen discusses his path into cell therapy and the evolving approaches to CMC, manufacturing, and commercialization
False
Catalent’s John Tomtishen discusses his path into cell therapy and the evolving approaches to CMC, manufacturing, and commercialization
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
November 17, 2026
6 min read
Regeneron’s Andres Sirulnik reflects on the experiences that took him from treating leukemia patients to developing medicines – and why following the science still means putting patients first
November 16, 2026
1 min read
CAR T pioneer John Maher reflects on the value of curiosity, career-defining setbacks, and pursuing unpopular ideas
November 13, 2026
1 min read
Fujifilm Cellular Dynamics’ Delara Motlagh discusses her path into cell and gene therapy, the challenges of scaling manufacturing, and the potential of iPSC technologies
November 11, 2026
2 min read
The deal adds viral vector, bioconjugation, payload-linker, and advanced drug-delivery capabilities to Lonza’s manufacturing network
False
Affiliations:
Specialties:
Areas of Expertise: